M Jabri

Netherlands Cancer Institute, Amsterdamo, North Holland, Netherlands

Are you M Jabri?

Claim your profile

Publications (3)5.09 Total impact

  • P Dumont · E P van der Esch · M Jabri · F Lejeune · G Atassi ·
    [Show abstract] [Hide abstract]
    ABSTRACT: In the subrenal capsule assay, the immuno-competent mice used have a host immune response to the graft which may introduce a bias in the determination of tumour size. A study was therefore conducted to verify the quality of the correlation that could exist between "macroscopical" and "microscopical" evaluation. A histological study of 12 different tumours treated with cis-Pt, L-PAM, DTIC, vindesine, BCNU or TGU demonstrated that a cellular host immune response was observed in 11 out of the 12 control groups and was uneven in the treated groups. The "microscopical" and "macroscopical" evaluations of tumour-take were 100 and 95% respectively. Although there was a fair correlation between the "microscopic" and "macroscopic" parameters, tumour variations in absence of host reaction--which reflect pure chemosensitivity of the treated tissue--could be measured in 50% of the cases. It was possible to determine a base-line for rejection of the test results when the control group showed a decrease in mean tumour size exceeding 20% of its initial size on day 0. If the decrease is less than 20%, then the histological evaluation appears to be of considerable additional value.
    International Journal of Cancer 04/1984; 33(4):447-51. DOI:10.1002/ijc.2910330405 · 5.09 Impact Factor
  • F J Lejeune · R Regnier · J M Nogaret · M Jabri ·
    [Show abstract] [Hide abstract]
    ABSTRACT: In order to avoid amputation, which does not seem to improve survival in osteosarcoma, we have initiated a limb-preservation program using intra-arterial radiosensitization. Eleven osteosarcomas with soft tissue involvement and six other bone malignancies were prospectively treated according to the following protocol: (a) surgical insertion of an intra-arterial catheter through a Dacron patch, (b) intra-arterial infusion of 15 mg/kg BUDR on days 1-2 every 5 days for 40 days, (c) 600 rads flash irradiation on day 3 every 5 days, X 8. Median follow-up time has been 36 months. In the osteosarcoma group, median survival has been 12 months. Four of the five osteosarcoma patients who died had received prophylactic HD methotrexate-vincristine-adriamycin systemic chemotherapy; one patient refused.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 02/1983; 86:204-8.
  • [Show abstract] [Hide abstract]
    ABSTRACT: In-transit metastases of melanoma of the limbs represent a challenging problem to the surgeon. Before the introduction of isolation perfusion, the only treatment available was major amputation, without there being evidence, however, of increased patient survival (McPeak et al. 1963; Miller 1977). Complete remissions after hyperthermic isolation perfusion with melphalan (HIPM) were reported by Stehlin et al. (1975) on some unexcised primaries and regional metastases of melanoma. However most authors (Au and Goldman 1979; Creech and Krementz 1964; Krementz and Ryan 1972; Martijn et al. 1981; Stehlin et al. 1975) have favored the policy of metastasis excision, followed or preceded by isolation perfusion. The rate of cure is between 50% and 75%, but it seems difficult to ascertain the value of adjuvant isolation perfusion because it is administered simultaneously with surgery.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 02/1983; 86:268-76. DOI:10.1007/978-3-642-82025-0_45